Immunomedics (IMMU) – StreetInsider.com Reports
-
FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer
-
Gilead Sciences (GILD) Completes Acquisition of Immunomedics (IMMU)
-
Gilead Sciences (GILD) Announces Expiration of HSR Waiting Period for Immunomedics (IMMU) Tender Offer
-
Immunomedics (IMMU) Announces FDA Orphan Drug Designation of Trodelvy for Adult and Pediatric Glioblastoma
-
UPDATE: Immunomedics (IMMU) granted orphan drug status for treatment of malignant glioma
-
Gilead Sciences (GILD) Prices $7.25 Billion of Senior Unsecured Notes
-
Gilead (GILD) to Sell $7.25B of Bonds to Fund Immunomedics (IMMU) Deal - Bloomberg
-
Immunomedics (IMMU) Announces Encouraging Early-Stage Clinical Results with Trodelvy in Brain Cancers
-
Gilead Sciences (GILD) PT Raised to $86 at RBC Capital Ahead of ESMO Conference
-
Buffett-backed Snowflake's value doubles in stock market's largest software debut
-
Increasing unusual put option volume: IMMU ANGI SWN SIRI ACI IEF MAT DVA AEO
-
Increasing unusual put option volume: IMMU SIRI ACI IEF AEO QD QRVO CPRI
-
Increasing unusual put option volume: IMMU QLD
-
Tech, healthcare mega deals boost virus-stricken M&A market
-
Immunomedics (IMMU) puts active into ESMO
-
Increasing unusual put option volume: IMMU APA MAT CSIQ EOG PSTG HAS
-
Jefferies Downgrades Immunomedics (IMMU) to Hold
-
Immunomedics (IMMU) out of the money option implied volatility increases into ESMO
-
Gilead's shares rise after $21 billion deal for Immunomedics
-
Immunomedics (IMMU) OTM puts active after Gilead (GILD) announced acquiring for $21B
-
Increasing unusual put option volume: IMMU CSIQ EOG IFF MXEF ORCL
-
Increasing unusual put option volume: IMMU UN
-
Pre-Open Stock Movers 09/14: (IMMU) (SGMS) (NVDA) Higher; (GILD) (MGM) (WMT) Lower (more...)
-
Gilead Sciences (GILD) Immunomedics (IMMU) Deal a Positive - Jefferies
-
Gilead (GILD) Locks Trodelvy with $21B Immunomedics (IMMU) Deal as Some Question High Price Tag
-
H.C. Wainwright Downgrades Immunomedics (IMMU) to Neutral
-
Wells Fargo Downgrades Immunomedics (IMMU) to Equal Weight
-
Immunomedics (IMMU) call put ratio 3.3 calls to 1 put into Gilead (GILD) acquiring for $21B
-
Gilead Sciences (GILD) to Acquire Immunomedics (IMMU) for $21 Billion
-
Immunomedics (IMMU) IV into Gilead (GILD) acquiring for $88 per share
-
Gilead (GILD) Near Deal to Acquire Immunomedics (IMMU) for More than $20B - WSJ
-
Immunomedics (IMMU) Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy
-
Immunomedics (IMMU) PT Raised to $40 at Morgan Stanley
-
Immunomedics (IMMU) PT Raised to $55 at Cowen
-
Immunomedics (IMMU) PT Raised to $55 at Guggenheim
-
Immunomedics (IMMU) PT Raised to $52 at Barclays
-
Immunomedics (IMMU) Sees Mid-Day Weakness
-
UPDATE: Immunomedics (IMMU) PT Raised to $55 at Jefferies; 'Survey Suggests Strong Trodelvy Launch'
-
AstraZeneca bets up to $6 billion on new Daiichi cancer drug
-
Immunomedics (IMMU) Reports Expanded Collaboration with Roche to Evaluate Trodelvy (sacituzumab govitecan-hziy) in Combination with Tecentriq (atezolizumab) into Urothelial & mNSCLC
-
Immunomedics (IMMU) PT Raised to $52 at Guggenheim
-
Immunomedics Inc. (IMMU) Well Positioned on the Back of Trodelvy Data - Cowen
-
Immunomedics (IMMU) PT Raised to $55 at Piper Sandler
-
Pre-Open Movers 07/06: (CRTO) (SBH) (TSLA) Higher; (OBSV) (VERI) (D) Lower (more...)
-
Immunomedics (IMMU) to Resume Trading at 8:25 a.m.
-
Immunomedics (IMMU) Phase 3 ASCENT Study of TRODELVY in Previously-Treated Patients with mTNBC Met Primary Endpoint
-
Immunomedics (IMMU) Halted. News Pending
-
Immunomedics (IMMU) PT Raised to $44 at BofA Securities, Sees Trodelvy Becoming 'Standard of Care'
-
Immunomedics (IMMU) PT Raised to $31 at Goldman Sachs
-
Immunomedics (IMMU) announces Harout Semerjian steps down from his role as CEO
Back to IMMU Stock Lookup